🚨FDA approves rilzabrutinib – 1st BTK inhibitor for ITP LUNA3: heavily pre-treated pts (median 4 prior lines, 28% splenectomy), durable PLT response 23% vs 0% PBO; 64% initial rise; median 15d. ↓ rescue Rx, ↓ bleeding, ↑ QoL. Well-tolerated Australia needs this! 🇦🇺 @thanzblood.bsky.social #hemesky

Results of HIPRO single centre RCT out In pts w/ provoked VTE + enduring risk (obesity, chronic inflammation, CVD, lung dz), 12 mo low-dose apixaban cut recurrence 1.3% vs 10% (HR 0.13, NNT≈12). Major bleed rare; CRNM bleed ↑ (NNH≈32). Subgroup analysis underpowered. www.nejm.org/doi/full/10....

Poll question for haematologists Is there still a role for Activated Protein C Resistance testing in the assessment for thrombophilia, when FVL PCR is readily available? 1️⃣ YES 2️⃣ NO Reply with number below. #hemesky

www.sciencedirect.com/science/arti... I came across this “practical guideline” for major heritable thrombophilia. I am not sure I agree with some of their recommendations - should generate an interesting debate though. Also have never tested for the F2 AT resistance mutations! #hemesky

Combined HbC trait and G6PD deficiency!

Biology resists simplicity #ISTH2025 plenary session

Personal highlights from day 2 of #ISTH2025 👇

Personal highlights from day 1 of #ISTH2025 👇

I think this drug will settle many an argument …. jamanetwork.com/journals/jam...

Fascinating paper; which reinforces my own clinical experience that the majority of clinically encountered type I protein S deficiency behave like a low risk thrombophilia, presumably as they have the missense variant. We need more studies like this! jamanetwork.com/journals/jam...

@isth.org #Hemesky

📢 Hematology Breakthrough! 🧑‍⚕️🔬 📌 Follow us for more updates: @displaycia.bsky.social 🔗 Read more: displaycia.com/medic... #Hematology #HealthScience #Breakthrough #MedicalScience #ManuscriptSubmission #ScientificResearch #Innovation #Displaycia

Bottom line - the LLN for Ferritin in both women and men should be at least 30 in the absence of inflammation and chronic kidney disease.

FARES-II: Much anticipated randomized trial @jama.com comparing Plasma to PCC in cardiac surgery (n=420) Those in PCC arm had ↑ hemostatic efficacy and ↓ RBC transfusion Hopefully practice-changing for many! jamanetwork.com/journals/jam... #transfusion #hemesky

Finally! More data to add to the EVE trial APICAT showed non inferiority of apixaban 2.5BD in patients with CAVTE who have completed 6m anticoagulation to 5BD in terms of VTE recurrence (2.1% v 2.8%) and lower clinically relevant bleeding (12.1% v 15.6%) #Hemesky #BSH www.nejm.org/doi/full/10....

doi.org/10.1182/hem.... This is a fantastic read. Strongly recommended. #Hemesky

New in The Journal of Haemophilia Practice: a paper reporting on the hopes and goals of a group of men with #haemophilia B, including how new treatments, such as #genetherapy, could help support and redefine their aspirations. Open access here: loom.ly/vJmE2Wg #HemeSky #BloodSky #MedSky

RPTH Cares about Women's Health 🌸: NAID and IDA are extremely prevalent among women, largely due to iron losses from vaginal blood loss. Explore the findings: www.rpthjournal.org/article/S247... @isth.org #IronDeficiency #WomensHealth

#ASHWomenWednesday ♀️🩸: Learn about why hematologists should care about heavy periods, and test your knowledge with a quick quiz. Share your insights in the comments! #ASHEducation #ASHWomenWednesday #WomenInHeme #Shematology #BloodSisters #HemeHeroines #BloodEducation #Microlearning #Hematology

Funny things patients say in clinic - part 1 “I don’t like those compression stockings for my post thrombotic syndrome. They’re tight” 🧐🧐🧐 #Hemesky

I have sympathy for Americans who can no longer access clinical trials due to politicization of healthcare by ignorant folk At the same time, I hope people can appreciate the lack of access to the most basic healthcare (which people take for granted) in >80% of the world, including many war zones.

Simple cheap intervention, low risk of side effects, improved outcomes for mum (lower PPH, lower risk RBC transfusion and allomunisation, feeling better in herself) and now for baby! This is ripe for low-middle income country quality improvement initiatives. @who.int

Latest publication in @haemophilia.bsky.social onlinelibrary.wiley.com/doi/10.1111/... #Hemesky

This week in @bloodjournal.bsky.social, data from the STOPAGO trial showed that almost half of patients who achieved remission from chronic ITP while on TPO receptor agonist therapy were able to stop their TPO-RA and remain in remission at four years. #hemesky #ITP

Since dreaming is free, here is my Haemostasis and Thrombosis Wishlist for 2025 (a 🧵) 1. Upfront Emicizumab for acquired Haemophilia A 2. Point of Care DOAC assays to dictate need for reversal (<50 vs >50) (1/4)

ascopubs.org/doi/10.1200/... <5% of 3345 leukaemia clinical trials between 2000-2020 have run in low-middle income countries. Healthcare is a human right and it truly is an injustice that access to novel therapies is denied to those who need it most in the world based on postcode lottery #Hemesky

#Hemesky What have you found most effective in the management of patients with recurrent IDA/GI bleeding and severe VWD/aVWS who have serial negative investigations? ☝️VWF concentrate prophylaxis 🤘Statins 🤟 Octeotide 🖖 steroids/hormonal treatments 🤚 IMiDs 👎 Nothing

The data for Emicizumab in AHA is increasingly robust. My experience is that these patients nowadays rarely die of bleeding but suffer greatly with the consequences of IST especially prolonged steroid therapy. I also strongly favour early use of steroid sparing therapy especially single dose Ritux.

doi.org/10.1182/bloo... This is a cool concept but not accessible to 99% of the world. Personally, I think we need a prospective multi-center RCT of cold storage platelets vs standard of care in patients with platelet function defects and high risk BDUCs requiring major surgery.

(2/2) 4. A(B)VD for cHL and RCHOP21 (for DLBCL) appear safe in 2nd and early 3rd trimester 5. Romiplostim an option for refractory ITP in pregnancy beyond 1st trimester 6. CP-CML in pregnancy - if you can wait, wait. Otherwise PLEX + PegIFN best. Some data for imatinib but not 2nd/3rd gen TKIs

Six takeaways from BSH Obs Haem Day (1/2) 1. Aggressive iron chelation prepubescence is key for fertility preservation in Thal Major (TDT) 2. Spermatogenesis induction in TDT males with secondary gonadal failure can take up to 2 yrs! 3. MDT approach to bleeding disorders in pregnancy

Really interesting paper. HIT CLIAs and ELISAs aren’t “positive” or “negative”. A probabilistic approach to interpretation is much more sensible.